Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients

Clin Otolaryngol. 2024 Jul;49(4):481-489. doi: 10.1111/coa.14172. Epub 2024 May 6.

Abstract

Introduction: Management of severe chronic rhinosinusitis with nasal polyps (CRSwNP) has changed significantly in recent years, with different treatments now available including biologics and endoscopic sinus surgery (ESS), although there are still few comparative studies. We aimed to compare 1-year outcomes of patients with severe CRSwNP treated with dupilumab or ESS plus intranasal corticosteroids (INCS).

Methods: In this retrospective, real-life, observational, cohort study, we enrolled 101 patients with severe CRSwNP who were treated with INCS and either ESS (n = 49) or dupilumab (n = 52). The following outcomes were considered: nasal polyp score (NPS), Sino Nasal Outcome Test-22 (SNOT-22), visual analogue scale (VAS) for specific symptoms, Sniffin' Sticks identification test (SSIT), need for oral corticosteroids (OCS) and local eosinophilia detected by nasal cytology.

Results: ΔNPS was significantly higher in the surgery group up to 12 months when the difference with dupilumab group was no longer significant (ΔNPS: 4 vs. 4.1). ΔVAS rhinorrhoea, ΔVAS smell and ΔSNOT-22 were significantly higher in the dupilumab group at 12 months (p < .05). SSIT scores were significantly better in the dupilumab group starting from the first month of follow-up (p < .05). In the dupilumab group, only 6.1% of patients had detectable local eosinophilia compared to 57% in the surgery group alongside with a lower need for OCS (16.3% vs. 61%).

Conclusions: Both dupilumab and ESS were effective in improving outcomes in patients with severe CRSwNP over 12 months. Nevertheless, patients treated with dupilumab had greater improvement in terms of SNOT-22, VAS rhinorrhoea, VAS smell and SSIT scores, with better control of local inflammation and less need for OCS.

Keywords: ESS; IL‐4; biologics; chronic rhinosinusitis; dupilumab; nasal polyps.

Publication types

  • Observational Study
  • Comparative Study

MeSH terms

  • Administration, Intranasal
  • Adult
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Chronic Disease
  • Endoscopy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasal Polyps* / complications
  • Nasal Polyps* / drug therapy
  • Nasal Polyps* / surgery
  • Retrospective Studies
  • Rhinitis* / complications
  • Rhinitis* / drug therapy
  • Rhinitis* / surgery
  • Severity of Illness Index
  • Sinusitis* / complications
  • Sinusitis* / drug therapy
  • Sinusitis* / surgery
  • Treatment Outcome

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized